Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MISSISSAUGA, ON, May 1, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013.
Help employers find you! Check out all the jobs and post your resume.
